Maternal immune stimulation reduces both placental morphologic damage and down-regulated placental growth-factor and cell cycle gene expression caused by urethane: are these events related to reduced teratogenesis?
Activation of the maternal immune system in mice decreased cleft palate caused by the chemical teratogen, urethane. Direct and indirect mechanisms for this phenomenon have been suggested, including maternal macrophages that cross the placenta to find and eliminate pre-teratogenic cells, or maternal immune proteins (cytokines) that cross placenta to alleviate or partially alleviate toxicant-mediated effects in the developing fetus. A third mechanism to explain improved fetal developmental outcome in teratogen-challenged pregnant mice might involve beneficial effects of immune stimulation on the placenta. In the present experiments, urethane treatment altered placental morphology and impaired placental function, the latter indicated by down-regulated activity of cell cycle genes and of genes encoding cytokines and growth factors. Maternal immune stimulation with either Freund's complete adjuvant (FCA) or interferon-gamma (IFNgamma) reduced morphologic damage to the placenta caused by urethane and normalized expression of several genes that were down-regulated by urethane. Urethane treatment also shifted placental cytokine gene expression toward a T cell helper 1 (Th1) profile, while immunostimulation tended to restore a Th2 profile that may be more beneficial to pregnancy and fetal development. These data suggest that the beneficial effects of maternal immune stimulation on fetal development in teratogen-exposed mice may, in part, result from improved placental structure and function.
Sharova
L V
LV
Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Phase II, Southgate Drive, Blacksburg, VA 24061-0442, USA.
Sharov
A A
AA
Sura
P
P
Gogal
R M
RM
Smith
B J
BJ
Holladay
S D
SD
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D018797:Cell Cycle Proteins / Q000096:biosynthesis* / Q000235:genetics; D002972:Cleft Palate / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D016207:Cytokines / Q000276:immunology; D015536:Down-Regulation / Q000235:genetics; D005314:Embryonic and Fetal Development / Q000187:drug effects / Q000276:immunology; D005260:Female; D018507:Gene Expression Regulation, Developmental; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010920:Placenta / Q000276:immunology* / Q000473:pathology; D000072483:Placenta Growth Factor; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000096:biosynthesis*; D013723:Teratogens / Q000633:toxicity*; D014520:Urethane / Q000633:toxicity*
D000276:Adjuvants, Immunologic; D018797:Cell Cycle Proteins; D016207:Cytokines; C000608037:Pgf protein, mouse; D011257:Pregnancy Proteins; D013723:Teratogens; D000072483:Placenta Growth Factor; D014520:Urethane